Multi-Aspect Optoacoustic Imaging of Breast Tumors under Chemotherapy with Exogenous and Endogenous Contrasts: Focus on Apoptosis and Hypoxia.
MSOT
breast cancer
contrast agent
molecular imaging
multispectral optoacoustic tomography
photoacoustics
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
16 Nov 2021
16 Nov 2021
Historique:
received:
27
07
2021
revised:
29
10
2021
accepted:
08
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Breast cancer is a complex tumor type involving many biological processes. Most chemotherapeutic agents exert their antitumoral effects by rapid induction of apoptosis. Another main feature of breast cancer is hypoxia, which may drive malignant progression and confer resistance to various forms of therapy. Thus, multi-aspect imaging of both tumor apoptosis and oxygenation in vivo would be of enormous value for the effective evaluation of therapy response. Herein, we demonstrate the capability of a hybrid imaging modality known as multispectral optoacoustic tomography (MSOT) to provide high-resolution, simultaneous imaging of tumor apoptosis and oxygenation, based on both the exogenous contrast of an apoptosis-targeting dye and the endogenous contrast of hemoglobin. MSOT imaging was applied on mice bearing orthotopic 4T1 breast tumors before and following treatment with doxorubicin. Apoptosis was monitored over time by imaging the distribution of xPLORE-APOFL750©, a highly sensitive poly-caspase binding apoptotic probe, within the tumors. Oxygenation was monitored by tracking the distribution of oxy- and deoxygenated hemoglobin within the same tumor areas. Doxorubicin treatment induced an increase in apoptosis-depending optoacoustic signal of xPLORE-APOFL750© at 24 h after treatment. Furthermore, our results showed spatial correspondence between xPLORE-APO750© and deoxygenated hemoglobin. In vivo apoptotic status of the tumor tissue was independently verified by ex vivo fluorescence analysis. Overall, our results provide a rationale for the use of MSOT as an effective tool for simultaneously investigating various aspects of tumor pathophysiology and potential effects of therapeutic regimes based on both endogenous and exogenous molecular contrasts.
Identifiants
pubmed: 34829925
pii: biomedicines9111696
doi: 10.3390/biomedicines9111696
pmc: PMC8615838
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : Sonderforschungsbereich-824 (SFB-824)
Références
PET Clin. 2018 Jul;13(3):445-457
pubmed: 30100082
J Oncol. 2010;2010:
pubmed: 20953378
Lancet Oncol. 2008 Oct;9(10):1002-11
pubmed: 18760670
Science. 1984 Oct 26;226(4673):466-8
pubmed: 6093249
Breast Cancer Res. 2007;9(4):212
pubmed: 17705880
Cancer Res. 2020 Dec 1;80(23):5291-5304
pubmed: 32994204
EJNMMI Res. 2012 Apr 01;2:14
pubmed: 22464315
Nat Rev Cancer. 2012 Apr 19;12(5):323-34
pubmed: 22513401
Curr Opin Pharmacol. 2003 Jun;3(3):317-22
pubmed: 12810199
Nat Protoc. 2011 Jul 07;6(8):1121-9
pubmed: 21738125
Nat Methods. 2016 Jul 28;13(8):639-50
pubmed: 27467727
Pharmacol Ther. 1990;47(2):219-31
pubmed: 2203071
Magn Reson Imaging. 2014 Dec;32(10):1344-52
pubmed: 25193110
Nat Rev Endocrinol. 2021 Jun;17(6):323-335
pubmed: 33875856
J Biomed Opt. 2011 Nov;16(11):116026
pubmed: 22112131
Nat Rev Cancer. 2002 Apr;2(4):277-88
pubmed: 12001989
Clin Cancer Res. 2008 Aug 15;14(16):5158-65
pubmed: 18698033
Photoacoustics. 2019 Mar 29;14:19-30
pubmed: 31024796
Molecules. 2018 Oct 25;23(11):
pubmed: 30366395
Photodiagnosis Photodyn Ther. 2020 Sep;31:101922
pubmed: 32726640
J Biophotonics. 2020 Jun;13(6):e201960169
pubmed: 32134550
Mol Metab. 2019 Feb;20:14-27
pubmed: 30580967
BMJ. 2001 Jun 23;322(7301):1528-32
pubmed: 11420276
N Engl J Med. 2017 Mar 30;376(13):1292-1294
pubmed: 28355498
Cell Metab. 2018 Mar 6;27(3):689-701.e4
pubmed: 29514074
Biochim Biophys Acta. 2016 Mar;1863(3):382-391
pubmed: 26079100
Nat Rev Cancer. 2005 Nov;5(11):876-85
pubmed: 16239906
J Nucl Med. 2016 Feb;57 Suppl 1:17S-26S
pubmed: 26834096
Photoacoustics. 2019 Jun 30;16:100134
pubmed: 31871887
Angew Chem Int Ed Engl. 2019 Apr 1;58(15):4886-4890
pubmed: 30688393
Sci Adv. 2020 Jun 12;6(24):eaaz6293
pubmed: 32582850
Clin Cancer Res. 2017 Nov 15;23(22):6893-6903
pubmed: 28821560
Carcinogenesis. 2005 Feb;26(2):263-70
pubmed: 15375012
Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1756-66
pubmed: 22890801
J Clin Pathol. 2004 Oct;57(10):1009-14
pubmed: 15452150
J Nucl Med. 2019 Oct;60(10):1461-1466
pubmed: 30850507
Mol Imaging Biol. 2011 Oct;13(5):1043-9
pubmed: 20835767
Cell Death Differ. 2001 Apr;8(4):367-76
pubmed: 11550088
Ann Transl Med. 2021 Jan;9(1):36
pubmed: 33553329
AJR Am J Roentgenol. 2006 Feb;186(2):308-19
pubmed: 16423932
Cancer Res. 1996 May 1;56(9):2161-6
pubmed: 8616866
Theranostics. 2016 Oct 7;6(13):2414-2430
pubmed: 27877244
Mol Metab. 2021 May;47:101184
pubmed: 33549846
Nat Med. 2019 Dec;25(12):1905-1915
pubmed: 31792454
JAMA Dermatol. 2018 Dec 1;154(12):1457-1462
pubmed: 30267083
Nat Med. 2009 Aug;15(8):967-73
pubmed: 19597506
Cell. 2018 Nov 29;175(6):1561-1574.e12
pubmed: 30449620
Opt Lett. 2014 Jun 15;39(12):3523-6
pubmed: 24978527
J Biomed Opt. 2016 Dec 1;21(12):126002
pubmed: 27918799
Photoacoustics. 2021 Jul 09;23:100283
pubmed: 34381689
Sci Rep. 2019 Nov 28;9(1):17847
pubmed: 31780739
Cancer Lett. 2003 May 8;194(1):125-31
pubmed: 12706866
N Engl J Med. 1981 Jul 16;305(3):139-53
pubmed: 7017406
Nat Commun. 2016 Jun 30;7:12121
pubmed: 27358000
Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1796-1805
pubmed: 28600647
J Invest Surg. 2005 Nov-Dec;18(6):335-50
pubmed: 16319055